within Pharmacolibrary.Drugs.ATC.J;

model J05AG05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.44,
    Cl             = 0.00023000000000000003,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 1.33,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00046666666666666666,
    Tlag           = 3000,            
    Vdp             = 1.58,
    k12             = 46.5,
    k21             = 46.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AG05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used as part of antiretroviral therapy for the treatment of HIV-1 infection in combination with other antiretroviral agents. It is approved for use in treatment-naïve adult patients with HIV-1 and is widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Taki, E, et al., &amp; Heidary, M (2022). Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV. <i>Expert review of anti-infective therapy</i> 20(8) 1135–1147. DOI:<a href=\"https://doi.org/10.1080/14787210.2022.2081153\">10.1080/14787210.2022.2081153</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35596583/\">https://pubmed.ncbi.nlm.nih.gov/35596583</a></p></li><li><p>Gaur, AH, et al., &amp; Bolton Moore, C (2024). Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study. <i>The lancet. HIV</i> 11(4) e211–e221. DOI:<a href=\"https://doi.org/10.1016/S2352-3018(23)00300-4\">10.1016/S2352-3018(23)00300-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38538160/\">https://pubmed.ncbi.nlm.nih.gov/38538160</a></p></li><li><p>Thoueille, P, et al., &amp; Guidi, M (2024). Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV. <i>Frontiers in pharmacology</i> 15 1437400–None. DOI:<a href=\"https://doi.org/10.3389/fphar.2024.1437400\">10.3389/fphar.2024.1437400</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39619609/\">https://pubmed.ncbi.nlm.nih.gov/39619609</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AG05;
